Polycystic Ovarian Disease in Adult and Perimenopausal Women

    January 2014 in “ Healthy aging research
    TLDR Polycystic ovarian disease symptoms can continue after menopause, making diagnosis and management in older women challenging.
    Polycystic ovarian disease (PCOD) is the most common endocrine disorder in women, characterized by a range of symptoms including hirsutism, menstrual irregularities, obesity, insulin resistance, and polycystic ovaries. Although the cause of PCOD is unknown, genetic studies suggest an autosomal dominant transmission with various hormonal disturbances. Symptoms can persist after menopause, making diagnosis in adult perimenopausal women challenging. Diagnosis often involves assessing the fasting glucose insulin ratio (FGI) and other lipid levels. Management focuses on symptom treatment and prevention of long-term complications, with oral contraceptive pills and insulin-sensitizing agents like metformin being common therapies. Long-term follow-up is necessary to evaluate the effectiveness of these treatments, especially in altering metabolic outcomes and managing issues like hair growth. Patient education on associated risks such as diabetes and cardiovascular disease is also crucial.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 25 results

      community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

      in Female  53 upvotes 1 year ago
      A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

      community AA and Hirsutism but T levels are normal

      in Female  8 upvotes 3 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community Does low HGH leading to hairloss?

      in Research/Science  12 upvotes 10 months ago
      The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

      community Spironolactone for 11 years, finasteride for almost 5 years, started oral minoxidil in November 😢 ended oral contraceptive in Dec.

      in Progress Pictures  224 upvotes 8 months ago
      A user shared their 11-year experience with spironolactone and nearly 5 years with finasteride for hair loss, recently adding oral minoxidil and stopping birth control. Various treatments were discussed, including organic options, checking for underlying health issues, considering dutasteride, and the potential role of progesterone in hair loss.

      community Finasteride 5mg & Spironolactone 100mg

      in Female  2 upvotes 3 weeks ago
      A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  105 upvotes 3 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

    Similar Research

    6 / 1000+ results